Developer docs
API playgroundTry for free, no card

Search company profiles

Ostro

Full company profile

uuid000058p

Namestring
Ostro
Legal namestring
Rise Healthcare Tech, Inc.
Websiteurl
ostrohealth.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Ostro is an AI-powered brand engagement platform purpose-built for the life sciences industry, serving pharmaceutical and biotechnology companies with conversational AI that delivers personalized, compliant interactions for both patients and healthcare professionals. The platform is built around a compliance-by-design architecture in which all AI-generated responses are grounded in each customer's MLR (Medical, Legal, Regulatory)-approved content, marketed as 100% compliant and hallucination-free via semantic search over approved materials. Its product suite comprises Ostro Sites (AI-powered web engagement for patients and HCPs on brand websites), Ostro Email (agent-led, two-way compliant inbox conversations with CRM and next-best-action integration), Ostro Consult (telehealth connecting patients to clinicians), and Ostro Navigate (HCP omnichannel engagement). Underlying AI capabilities include conversational AI, semantic search, generative AI, natural language processing, and recommendation engines layered on top of each customer's proprietary approved content corpus.

Ostro operates a B2B enterprise SaaS model, selling annual subscription contracts to top global biopharma companies through direct enterprise field sales (with "Get a Demo" and "Schedule a Demo" CTAs driving the funnel), and reportedly serves 8 of the top 10 biopharma and most of the top 20 global pharmaceutical companies, including Alexion, Gilead, Johnson & Johnson, BeOne, Ferring, and BridgeBio across 50+ brand deployments. The company was founded in 2019 as RxDefine, rebranded to Ostro in November 2022 alongside a $45 million funding round that brought total funding to over $55 million, and was acquired by Veeva Systems in March 2026 for approximately $100 million in cash and long-term equity retention grants. Following the acquisition, Ostro operates as an independent unit within Veeva's Commercial Cloud suite under continuing CEO Chase Feiger, with planned integrations between Ostro's products and Veeva's enterprise life sciences applications. The company is headquartered in Miami, Florida (incorporated in Delaware as Rise Healthcare Tech, Inc.) and has scaled to 51-100 employees.

Short descriptiontext

Ostro is an AI-powered brand engagement platform for life sciences that delivers conversational, MLR-compliant patient and HCP engagement via AI-driven web, email, and telehealth products to top global biopharma companies.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMiami, United States
HQ citystring
Miami
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI brand engagement, conversational AI platform, life sciences engagement, HCP patient engagement, pharmaceutical marketing software
Industry3 codes
PRIMARYBPAFAFAI
Customer Engagement & Messaging (Email, SMS, Push, In-App)
SECONDARYHLACAEAE
Patient Education, Content & Personalized Journey Orchestration
Healthcare & Life Sciences/Digital Health & Health IT/Patient Engagement, CRM & Experience Platforms
SECONDARYHLACAEAO
Patient Relationship Management (PRM) & CRM for Provider Growth (Marketing/Outreach)
Healthcare & Life Sciences/Digital Health & Health IT/Patient Engagement, CRM & Experience Platforms
NAICS code1 code
  • Custom Computer Programming Services541511
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Health Services8000
Product category
Pharmaceutical Marketing & Life Sciences Engagement Software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1SaaS Platform Licensing
TypeSubscription Recurring
Description

B2B SaaS subscription model providing AI-powered brand engagement platform to life sciences companies. Platform fees likely based on brand engagement volume, number of HCP/patient interactions, and feature tiers.

ostro.veeva.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Enterprise platform with customizable engagement modules
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing for enterprise life sciences companies. Specific tiers and price points not publicly disclosed.

ostro.veeva.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1Veeva Ostro
Description

The brand engagement platform for life sciences under Veeva, providing AI-powered conversational AI for patients and healthcare professionals.

ostro.veeva.com
+4 more records
Core offering1 text field

Ostro is an AI-powered brand engagement platform for life sciences companies that delivers personalized, MLR-compliant conversational experiences to patients and healthcare professionals (HCPs) across brand websites, email, and telehealth channels. The platform combines conversational AI, semantic search over approved content, and behavioral analytics to help biopharma brands drive high-value actions such as new-to-brand patient enrollment and competitive therapy switching.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 7x lift in specific high-value actions
+4 more records
Product overview1 text field

Ostro is an AI-powered brand engagement platform for life sciences, now part of Veeva Systems following a ~$100M acquisition in March 2026. The platform consists of three core products: Ostro Sites (AI-powered web engagement for patients and HCPs on brand websites), Ostro Email (AI-driven two-way compliant email conversations with HCPs), and Ostro Consult (telehealth integration connecting patients to clinicians). An additional module, Ostro Navigate, extends HCP engagement across omnichannel strategies. The product portfolio delivers personalized 1:1 healthcare journeys, combining conversational AI, semantic search over MLR-approved content, and live Nurse Navigator support to drive treatment confidence, high-value patient actions, and compliant HCP engagement. Formerly known as RxDefine, Ostro rebranded in November 2022 alongside a $45M funding round bringing total funding to over $55M.

Product and service4 records
1Ostro Sites
CategoryCore product — AI-powered web engagement
2Ostro Email
CategoryCore product — AI-powered email engagement
3Ostro Consult
CategoryAdd-on module — telehealth integration
4Ostro Navigate
CategoryAdd-on module — HCP omnichannel engagement
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-16
Description

Havas invested in Ostro to enhance its media and creative operations. The investment provides Havas access to Ostro's technology for its global ecosystem and supports clients in the health network. Havas committed nearly €1 billion to Converged.AI strategy including Ostro acquisition.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Aktana is an AI-driven commercial engagement platform for life sciences that coordinates HCP and patient interactions across channels for pharma brands. It directly competes with Ostro's agentic engagement layer and shares the same top-biopharma buyer.

TypeDirect peer
Description

Swoop (formerly Swoop and IPM.ai) provides AI-driven HCP and patient engagement, including conversational and targeted marketing for pharma brands. It is a like-for-like peer competing for the same conversational patient-journey wallet.

TypeDirect peer
Description

Concentra (formerly Concentra Analytics) is a life-sciences commercial analytics and engagement vendor delivering AI-driven HCP and patient activation for pharma brands. Closely comparable to Ostro's brand-engagement value proposition.

TypeDirect peer
Description

OptimizeRx operates a digital health messaging network connecting pharma brands with HCPs and patients at the point-of-prescribe. Comparable to Ostro in targeting biopharma brand teams with AI-enabled HCP/patient engagement.

TypeEmerging player
Description

PatientPoint delivers patient and HCP engagement content at the point of care via digital screens, tablets, and print. It overlaps with Ostro in pharma-sponsored patient engagement but operates through a distinct in-office channel.

TypeEmerging player
Description

Outcome Health provides health-content engagement at the point of care for pharma and life-sciences sponsors, including patient education and HCP resources. Comparable as a pharma-funded patient engagement platform, though via in-office media rather than web/email.

TypeBroad incumbent
Description

Veeva Systems is the parent company of Ostro post-2026 acquisition and the dominant life-sciences CRM/commercial cloud vendor. Its Veeva Commercial Cloud overlaps Ostro's buyer, content, and engagement workflows, making it a broad incumbent peer.

TypeBroad incumbent
Description

IQVIA is a global life-sciences services and technology provider whose Orchestrated Customer Engagement (OCE) platform offers AI-driven HCP and patient engagement for pharma. Comparable as a broader-suite incumbent competing for the same commercial-engagement budget.

TypeBroad incumbent
Description

Doximity is a digital platform for physicians with HCP-targeted engagement products used by pharma for marketing, content, and messaging. Comparable to Ostro's HCP engagement capabilities, though anchored in a physician network rather than brand websites.

TypeEmerging player
Description

Medisafe provides digital medication adherence and patient engagement tools that pharma sponsors offer to patients on therapy. It overlaps with Ostro's patient-journey engagement layer but is focused on adherence rather than conversational brand engagement.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ostro

Pharmaceutical Marketing & Life Sciences Engagement Softwareostrohealth.com

Ostro is an AI-powered brand engagement platform for life sciences that delivers conversational, MLR-compliant patient and HCP engagement via AI-driven web, email, and telehealth products to top global biopharma companies.

What Ostro does

Ostro is an AI-powered brand engagement platform purpose-built for the life sciences industry, serving pharmaceutical and biotechnology companies with conversational AI that delivers personalized, compliant interactions for both patients and healthcare professionals. The platform is built around a compliance-by-design architecture in which all AI-generated responses are grounded in each customer's MLR (Medical, Legal, Regulatory)-approved content, marketed as 100% compliant and hallucination-free via semantic search over approved materials. Its product suite comprises Ostro Sites (AI-powered web engagement for patients and HCPs on brand websites), Ostro Email (agent-led, two-way compliant inbox conversations with CRM and next-best-action integration), Ostro Consult (telehealth connecting patients to clinicians), and Ostro Navigate (HCP omnichannel engagement). Underlying AI capabilities include conversational AI, semantic search, generative AI, natural language processing, and recommendation engines layered on top of each customer's proprietary approved content corpus.

Ostro operates a B2B enterprise SaaS model, selling annual subscription contracts to top global biopharma companies through direct enterprise field sales (with "Get a Demo" and "Schedule a Demo" CTAs driving the funnel), and reportedly serves 8 of the top 10 biopharma and most of the top 20 global pharmaceutical companies, including Alexion, Gilead, Johnson & Johnson, BeOne, Ferring, and BridgeBio across 50+ brand deployments. The company was founded in 2019 as RxDefine, rebranded to Ostro in November 2022 alongside a $45 million funding round that brought total funding to over $55 million, and was acquired by Veeva Systems in March 2026 for approximately $100 million in cash and long-term equity retention grants. Following the acquisition, Ostro operates as an independent unit within Veeva's Commercial Cloud suite under continuing CEO Chase Feiger, with planned integrations between Ostro's products and Veeva's enterprise life sciences applications. The company is headquartered in Miami, Florida (incorporated in Delaware as Rise Healthcare Tech, Inc.) and has scaled to 51-100 employees.

Ostro firmographics

Firmographics
Name
Ostro
Legal name
Rise Healthcare Tech, Inc.
Website
https://ostrohealth.com
Company type
Private
Founded year
2019
Operating status
Acquired
Headcount range
51–100 employees
Short description
Ostro is an AI-powered brand engagement platform for life sciences that delivers conversational, MLR-compliant patient and HCP engagement via AI-driven web, email, and telehealth products to top global biopharma companies.
Ownership category
akta.pro rank

Ostro industry classification

Industry
Product category
Pharmaceutical Marketing & Life Sciences Engagement Software
NAICS
Custom Computer Programming Services (541511)
SIC
Services-Prepackaged Software (7372), Services-Health Services (8000)
akta.pro industry
PRIMARYBPAFAFAI
Customer Engagement & Messaging (Email, SMS, Push, In-App)
SECONDARYHLACAEAE
Patient Education, Content & Personalized Journey Orchestration
Healthcare & Life Sciences/Digital Health & Health IT/Patient Engagement, CRM & Experience Platforms
SECONDARYHLACAEAO
Patient Relationship Management (PRM) & CRM for Provider Growth (Marketing/Outreach)
Healthcare & Life Sciences/Digital Health & Health IT/Patient Engagement, CRM & Experience Platforms

Keywords

  • AI brand engagement
  • Conversational AI platform
  • Life sciences engagement
  • HCP patient engagement
  • Pharmaceutical marketing software

Where Ostro is headquartered

Location

Headquarters

HQ city
Miami
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Ostro business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. SaaS Platform Licensing: B2B SaaS subscription model providing AI-powered brand engagement platform to life sciences companies. Platform fees likely based on brand engagement volume, number of HCP/patient interactions, and feature tiers.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise platform with customizable engagement modules

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Ostro product offering

Product offering

Core offering

Ostro is an AI-powered brand engagement platform for life sciences companies that delivers personalized, MLR-compliant conversational experiences to patients and healthcare professionals (HCPs) across brand websites, email, and telehealth channels. The platform combines conversational AI, semantic search over approved content, and behavioral analytics to help biopharma brands drive high-value actions such as new-to-brand patient enrollment and competitive therapy switching.

Product overview

Ostro is an AI-powered brand engagement platform for life sciences, now part of Veeva Systems following a ~$100M acquisition in March 2026. The platform consists of three core products: Ostro Sites (AI-powered web engagement for patients and HCPs on brand websites), Ostro Email (AI-driven two-way compliant email conversations with HCPs), and Ostro Consult (telehealth integration connecting patients to clinicians). An additional module, Ostro Navigate, extends HCP engagement across omnichannel strategies. The product portfolio delivers personalized 1:1 healthcare journeys, combining conversational AI, semantic search over MLR-approved content, and live Nurse Navigator support to drive treatment confidence, high-value patient actions, and compliant HCP engagement. Formerly known as RxDefine, Ostro rebranded in November 2022 alongside a $45M funding round bringing total funding to over $55M.

Differentiator

Problem solved

Functional benefit

Brands

  • Veeva Ostro: The brand engagement platform for life sciences under Veeva, providing AI-powered conversational AI for patients and healthcare professionals.
  • Ostro Sites
  • Ostro Email
  • Ostro Consult
  • Ostro Navigate

Products and services

  • Ostro Sites
  • Ostro Email
  • Ostro Consult
  • Ostro Navigate

Quantifiable outcome

  • 7x lift in specific high-value actions
  • +4 more outcomes

Companies that use Ostro

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles1 record

Ostro technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Ostro partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Havas Health NetworkcoreStrategic or Co-development Partner · 16 December 2022Havas invested in Ostro to enhance its media and creative operations. The investment provides Havas access to Ostro's technology for its global ecosystem and supports clients in the health network. Havas committed nearly €1 billion to Converged.AI strategy including Ostro acquisition.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Ostro competitors and assessment

Company assessment

Direct peers

  • Aktana: Aktana is an AI-driven commercial engagement platform for life sciences that coordinates HCP and patient interactions across channels for pharma brands. It directly competes with Ostro's agentic engagement layer and shares the same top-biopharma buyer.
  • Swoop: Swoop (formerly Swoop and IPM.ai) provides AI-driven HCP and patient engagement, including conversational and targeted marketing for pharma brands. It is a like-for-like peer competing for the same conversational patient-journey wallet.
  • Concentra: Concentra (formerly Concentra Analytics) is a life-sciences commercial analytics and engagement vendor delivering AI-driven HCP and patient activation for pharma brands. Closely comparable to Ostro's brand-engagement value proposition.
  • OptimizeRx: OptimizeRx operates a digital health messaging network connecting pharma brands with HCPs and patients at the point-of-prescribe. Comparable to Ostro in targeting biopharma brand teams with AI-enabled HCP/patient engagement.

Emerging players

  • PatientPoint: PatientPoint delivers patient and HCP engagement content at the point of care via digital screens, tablets, and print. It overlaps with Ostro in pharma-sponsored patient engagement but operates through a distinct in-office channel.
  • Outcome Health: Outcome Health provides health-content engagement at the point of care for pharma and life-sciences sponsors, including patient education and HCP resources. Comparable as a pharma-funded patient engagement platform, though via in-office media rather than web/email.
  • Medisafe: Medisafe provides digital medication adherence and patient engagement tools that pharma sponsors offer to patients on therapy. It overlaps with Ostro's patient-journey engagement layer but is focused on adherence rather than conversational brand engagement.

Broad incumbents

  • Veeva Systems: Veeva Systems is the parent company of Ostro post-2026 acquisition and the dominant life-sciences CRM/commercial cloud vendor. Its Veeva Commercial Cloud overlaps Ostro's buyer, content, and engagement workflows, making it a broad incumbent peer.
  • IQVIA: IQVIA is a global life-sciences services and technology provider whose Orchestrated Customer Engagement (OCE) platform offers AI-driven HCP and patient engagement for pharma. Comparable as a broader-suite incumbent competing for the same commercial-engagement budget.
  • Doximity: Doximity is a digital platform for physicians with HCP-targeted engagement products used by pharma for marketing, content, and messaging. Comparable to Ostro's HCP engagement capabilities, though anchored in a physician network rather than brand websites.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Ostro social profiles

Digital presence

Ostro financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ostro leadership team

Management profile

Number of profiles

Profiles6 records

Ostro funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ostro M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ostro

What does Ostro do?

Ostro is an AI-powered brand engagement platform for life sciences companies that delivers personalized, MLR-compliant conversational experiences to patients and healthcare professionals (HCPs) across brand websites, email, and telehealth channels. The platform combines conversational AI, semantic search over approved content, and behavioral analytics to help biopharma brands drive high-value actions such as new-to-brand patient enrollment and competitive therapy switching.

Is Ostro a public or private company?

Ostro is a private company. It is classified as corporate owned and is currently acquired.

When was Ostro founded?

Ostro was founded in 2019. It employs 51 to 100 people.

Where is Ostro based?

Ostro is headquartered in Miami, United States, in the North America region.

How does Ostro make money?

One revenue line is on record: saaS Platform Licensing.

Who are Ostro's main competitors?

Direct peers on record are Aktana, Swoop, Concentra and OptimizeRx. Emerging players are PatientPoint, Outcome Health and Medisafe. Broad incumbents are Veeva Systems, IQVIA and Doximity.

Does Ostro have an API?

No public API is recorded for Ostro.

What industry is Ostro in?

Ostro's product category is Pharmaceutical Marketing & Life Sciences Engagement Software. Its primary akta.pro industry code is BPAFAFAI, Customer Engagement & Messaging (Email, SMS, Push, In-App), with a secondary code of HLACAEAE, Patient Education, Content & Personalized Journey Orchestration. Its NAICS code is 541511 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
//telecareaware.com/Silicon Valley Bank’s take on H1 investment: among the “have and have nots”, it was “the best half in years” for health techSVB's H1 2026 healthcare investment roundup shows health tech investment rose to $7.2 billion, the best half since 2022, but deals fell to 203. Total healthcare investment was $24.7 billion, down from $25.8 billion in H2 2025, with 618 deals. The report notes AI-driven growth and a shift toward Series C+ deals.StockStoryVEEV Q1 Deep Dive: AI-Driven Product Expansion and New Platform Initiatives Highlight QuarterVeeva Systems (VEEV) reported Q1 CY2026 earnings beating Wall Street expectations with revenue of $882.9 million, up 16.3% year-on-year and 2.9% above analyst estimates of $857.8 million. The company raised its full-year revenue guidance to $3.64 billion at the midpoint and adjusted EPS guidance to $9.05, while launching its AI-driven Falcon platform designed to automate specialized life sciences industry tasks through "agentic labor." Management highlighted the Ostro acquisition integration and continued momentum in Crossix analytics as key drivers of its updated outlook.Investing.comVeeva Systems beats estimates on AI progress By Investing.comVeeva Systems Inc reported first-quarter results that exceeded analyst expectations, with adjusted EPS of $2.24 beating the $2.14 consensus estimate and revenue of $882.9 million surpassing the $857.75 million forecast while growing 16% year-over-year. The life sciences software provider issued guidance above Wall Street expectations for both the second quarter and full fiscal year 2027, forecasting revenue of $902-905 million for Q2 and $3.635-3.645 billion for FY2027, with adjusted EPS guidance of $9.05 for the full year exceeding the $8.87 estimate. The company also completed its acquisition of Ostro in March and added 27 new Vault CRM customers, bringing the total to over 150 customers on the platform.Stock TitanVeeva Systems Q1 revenue up 16%, lifts 2027 viewVeeva Systems reported fiscal Q1 2027 results for the quarter ended April 30, 2026, with total revenues of $882.9 million, up 16% year over year, driven by 15% subscription revenue growth to $730.2 million. The company exceeded guidance on all metrics, with operating income up 17% to $273.1 million and net income up 14% to $260.9 million. Veeva raised its full-year fiscal 2027 guidance to $3.635–3.645 billion in total revenues and announced significant AI strategy progress including its Ostro acquisition, Vault AI expansion, and planned Veeva Falcon platform release.YahooVeeva Systems (VEEV) Announces Acquisition of OstroVeeva Systems Inc. announced the acquisition of Ostro for approximately $100 million in cash plus long-term equity retention grants. Ostro, a leading brand engagement platform for life sciences, will operate as an independent unit under CEO Chase Feiger. The deal focuses on developing integrations between Ostro's AI-led chat platform and Veeva Commercial Cloud applications to enhance patient and doctor engagement workflows.ClinicaltrialvanguardThe Trusted Source: How Veeva’s Acquisition of Ostro Is Rewriting How Patients and Doctors Get Drug InformationVeeva Systems acquired Ostro, an AI-powered brand engagement platform, in March 2026 for $100 million, marking a strategic expansion into direct patient and healthcare professional communication. The acquisition reflects Veeva's belief that AI-driven information delivery will transform how patients and HCPs access drug and disease information, with Ostro's technology specifically designed to provide accurate, hallucination-free answers within approved content guardrails. Veeva CEO Paul Shawah emphasized the deal was chosen over internal development because Ostro already has proven traction, customers, and the technical infrastructure to deliver consistent accuracy at scale.FiercePharmaVeeva shells out $100M for Ostro and its AI chat tool for pharma brand engagementVeeva Systems announced the acquisition of Ostro, a healthcare AI company, for approximately $100 million in a combination of cash and long-term equity retention grants. Ostro has developed an AI-powered chat tool for pharmaceutical companies that provides patients and clinicians with drug information from approved, compliant materials, integrated into brands' websites, emails, and text messages. Post-acquisition, Ostro will operate as an independent unit under Veeva while the companies plan to integrate Ostro's technology with Veeva's cloud-based software to connect online and in-the-field interactions with patients and doctors.Pulse 2.0Veeva Systems: $100 Million Acquisition Of Ostro To Expand AI-Powered Brand Engagement In Life SciencesVeeva Systems acquired Ostro, an AI-driven brand engagement platform for life sciences, in a deal valued at approximately $100 million in cash plus equity grants. Ostro provides conversational AI that delivers compliant answers from approved materials, and will operate as an independent unit before integration with Veeva's Commercial Cloud.pharmaphorumVeeva buys brand engagement firm Ostro for $100mVeeva Systems has acquired Ostro, a Miami-based AI start-up focused on pharma brand engagement, for approximately $100 million in cash and long-term equity retention grants. The deal will integrate Ostro's conversational AI platform into Veeva's Commercial Cloud suite, enabling pharmaceutical companies to deliver compliant, tailored content to healthcare professionals and patients. This acquisition marks Veeva's second purchase this year following the Yanalink deal, building on the company's reported 16% revenue growth to $3.2 billion.Investing.comVeeva Systems acquires Ostro for approximately $100 million By Investing.comVeeva Systems announced the acquisition of Ostro, a brand engagement platform for life sciences companies, for approximately $100 million in cash and long-term equity retention grants. Ostro provides AI-driven chat technology that enables patients and healthcare professionals to receive compliant answers through brand websites, with the acquisition aimed at enhancing customer access to medical information. Ostro will operate as an independent unit under CEO Chase Feiger, with plans to integrate its technology with Veeva Commercial Cloud applications.